Literature DB >> 7908619

A new proposal for benefit-less-risk analysis in clinical trials.

C Chuang-Stein1.   

Abstract

In this paper, we propose a method to discount the observed benefit of a treatment by the observed risk in order to facilitate the benefit-less-risk comparison of treatments in a clinical trial. The discounting, applied to each individual in a trial, utilizes a method proposed by Chuang-Stein and co-authors to consolidate the safety data collected in the trial. The collating of the safety information allows one to estimate quantitatively the risk experienced by each individual, and therefore enables the construction of a risk-adjusted benefit measure for the same individual. We discuss the rationale for the adjusting method and examine its impact on the inference. When the discounting process reflects an individual's choice, the results should be interpreted at the individual level. An example is given to illustrate the approach.

Mesh:

Substances:

Year:  1994        PMID: 7908619     DOI: 10.1016/0197-2456(94)90026-4

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  9 in total

Review 1.  Benefit-risk analysis : a brief review and proposed quantitative approaches.

Authors:  William L Holden
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Defining Study Outcomes That Better Reflect Individual Response to Treatment.

Authors:  Konstantia Angelidou; Paul Palumbo; Jane Lindsey; Avy Violary; Moherndran Archary; Linda Barlow; Brian Claggett; Michael Hughes; Lee-Jen Wei
Journal:  Pediatr Infect Dis J       Date:  2018-03       Impact factor: 2.129

Review 3.  Ethical considerations in neuroclinical trials.

Authors:  S N Macciocchi; W A Alves
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

Review 4.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

5.  Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2016-12-06       Impact factor: 1.452

6.  The Role of Intuition in Risk/Benefit Decision-Making in Human Subjects Research.

Authors:  David B Resnik
Journal:  Account Res       Date:  2016-06-13       Impact factor: 2.622

Review 7.  A framework for organizing and selecting quantitative approaches for benefit-harm assessment.

Authors:  Milo A Puhan; Sonal Singh; Carlos O Weiss; Ravi Varadhan; Cynthia M Boyd
Journal:  BMC Med Res Methodol       Date:  2012-11-19       Impact factor: 4.615

8.  Joint distribution approaches to simultaneously quantifying benefit and risk.

Authors:  Michele L Shaffer; Kristi L Watterberg
Journal:  BMC Med Res Methodol       Date:  2006-10-12       Impact factor: 4.615

9.  Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD.

Authors:  Milo A Puhan; Tsung Yu; Cynthia M Boyd; Gerben Ter Riet
Journal:  BMC Med       Date:  2015-07-02       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.